Apex Healthcare Competitors and Similar CompaniesClear all

Apex Healthcare's competitors and similar companies include Chartwell Pharmaceuticals, Caprico Biotechnologies, Biosonda and Hubei Guangji Pharmaceutical.

	Apex Healthcare Apex Healthcare is a company that manufactures and markets pharmaceutical and consumer healthcare products.	Chartwell Pharmaceuticals Chartwell Pharmaceuticals is a manufacturing, packaging, and related supply chain services organization.	Caprico Biotechnologies Caprico Biotechnologies (CBI) is a biotech company focused on developing and commercializing antibody reagents for flow cytometry applications.	Biosonda Biosonda is a biotechnology company that specializes in the research, development, production, and commercialization of hemocyanins.	Hubei Guangji Pharmaceutical Hubei Guangji Pharmaceutical (湖北广济药业股份有限公司) is a distributor of drugs and pharmaceutical raw materials.
Founding Date	Founding Date 1967	Founding Date 2010	Founding Date 2013	Founding Date 1992	Founding Date 1969
Type	Type Public	Type Private	Type Private	Type Private	Type Public
Tags	Tags Healthcare clinical research distribution drug development pharma	Tags Healthcare clinical research distribution drug development pharma supply chain	Tags Healthcare biotech clinical research distribution drug development pharma	Tags Healthcare biotech clinical research distribution drug development pharma	Tags Healthcare chemicals clinical research distribution drug development pharma
Locations	Locations HQ	Locations Congers, US HQ	Locations Norcross, US HQ	Locations Miami, US HQ Ñuñoa, CL	Locations Huanggang, CN HQ
Employees	Employees N/A	Employees 1142% decrease	Employees 17	Employees N/A	Employees 1,39825% decrease
Financial
Revenue (est.)	Revenue (est.) RM961.8m (FY, 2024)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) ¥619.5m (FY, 2024)
Cost of goods	Cost of goods RM707.7m (FY, 2024)	Cost of goods N/A	Cost of goods N/A	Cost of goods N/A	Cost of goods ¥519.1m (FY, 2024)
Gross profit	Gross profit RM261.6m (FY, 2024)	Gross profit N/A	Gross profit N/A	Gross profit N/A	Gross profit ¥104.1m (FY, 2024)
Net income	Net income RM76.5m (FY, 2024)	Net income N/A	Net income N/A	Net income N/A	Net income (¥315.1m) (FY, 2024)